J L Vosters1, N Roescher, G G Illei, J A Chiorini, P P Tak. 1. Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands. j.l.vosters@amc.uva.nl
Abstract
OBJECTIVE: Patients with Sjögren's syndrome (SS) show aberrant expression of the B cell-related mediators, B cell-activating factor (BAFF), and a proliferation-inducing ligand (APRIL) in serum and salivary glands (SGs). We studied the biological effect of neutralizing these cytokines by local gene transfer of the common receptor transmembrane activator and CAML interactor (TACI) in an animal model of SS. MATERIAL AND METHODS: A recombinant serotype 2 adeno-associated virus (rAAV2) encoding TACI-Fc was constructed, and its efficacy was tested in the SGs of non-obese diabetic mice. Ten weeks later, SG inflammation was evaluated and serum and SG tissue were analyzed for inflammatory markers including immunoglobulins (Ig) and cytokines. RESULTS: AAV2-TACI-Fc gene therapy significantly reduced the number of inflammatory foci in the SG, owing to a decrease in IgD(+) cells and CD138(+) cells. Moreover, IgG and IgM levels, but not IgA levels, were reduced in the SG. Overall expression of mainly proinflammatory cytokines tended to be lower in AAV2-TACI-Fc-treated mice. Salivary flow was unaffected. CONCLUSION: Although local expression of soluble TACI-Fc reduced inflammation and immunoglobulin levels in the SG, further research will have to prove whether dual blockade of APRIL and BAFF by TACI-Fc can provide a satisfying treatment for the clinical symptoms of patients.
OBJECTIVE:Patients with Sjögren's syndrome (SS) show aberrant expression of the B cell-related mediators, B cell-activating factor (BAFF), and a proliferation-inducing ligand (APRIL) in serum and salivary glands (SGs). We studied the biological effect of neutralizing these cytokines by local gene transfer of the common receptor transmembrane activator and CAML interactor (TACI) in an animal model of SS. MATERIAL AND METHODS: A recombinant serotype 2 adeno-associated virus (rAAV2) encoding TACI-Fc was constructed, and its efficacy was tested in the SGs of non-obese diabeticmice. Ten weeks later, SG inflammation was evaluated and serum and SG tissue were analyzed for inflammatory markers including immunoglobulins (Ig) and cytokines. RESULTS:AAV2-TACI-Fc gene therapy significantly reduced the number of inflammatory foci in the SG, owing to a decrease in IgD(+) cells and CD138(+) cells. Moreover, IgG and IgM levels, but not IgA levels, were reduced in the SG. Overall expression of mainly proinflammatory cytokines tended to be lower in AAV2-TACI-Fc-treated mice. Salivary flow was unaffected. CONCLUSION: Although local expression of soluble TACI-Fc reduced inflammation and immunoglobulin levels in the SG, further research will have to prove whether dual blockade of APRIL and BAFF by TACI-Fc can provide a satisfying treatment for the clinical symptoms of patients.
Authors: Stina Salomonsson; Malin V Jonsson; Kathrine Skarstein; Karl A Brokstad; Peter Hjelmström; Marie Wahren-Herlenius; Roland Jonsson Journal: Arthritis Rheum Date: 2003-11
Authors: P Barrera; L A Joosten; A A den Broeder; L B van de Putte; P L van Riel; W B van den Berg Journal: Ann Rheum Dis Date: 2001-07 Impact factor: 19.103
Authors: Joanna Groom; Susan L Kalled; Anne H Cutler; Carl Olson; Stephen A Woodcock; Pascal Schneider; Jurg Tschopp; Teresa G Cachero; Marcel Batten; Julie Wheway; Davide Mauri; Dana Cavill; Tom P Gordon; Charles R Mackay; Fabienne Mackay Journal: J Clin Invest Date: 2002-01 Impact factor: 14.808
Authors: J A Gross; S R Dillon; S Mudri; J Johnston; A Littau; R Roque; M Rixon; O Schou; K P Foley; H Haugen; S McMillen; K Waggie; R W Schreckhise; K Shoemaker; T Vu; M Moore; A Grossman; C H Clegg Journal: Immunity Date: 2001-08 Impact factor: 31.745
Authors: H Wang; S A Marsters; T Baker; B Chan; W P Lee; L Fu; D Tumas; M Yan; V M Dixit; A Ashkenazi; I S Grewal Journal: Nat Immunol Date: 2001-07 Impact factor: 25.606
Authors: Arne Hansen; Marcus Odendahl; Karin Reiter; Annett M Jacobi; Eugen Feist; Jürgen Scholze; Gerd R Burmester; Peter E Lipsky; Thomas Dörner Journal: Arthritis Rheum Date: 2002-08
Authors: Antonis Voutetakis; Marc R Kok; Changyu Zheng; Ioannis Bossis; Jianghua Wang; Ana P Cotrim; Natanya Marracino; Corinne M Goldsmith; John A Chiorini; Y Peng Loh; Lynnette K Nieman; Bruce J Baum Journal: Proc Natl Acad Sci U S A Date: 2004-02-20 Impact factor: 11.205
Authors: Jens V Stein; Marta López-Fraga; Fernando A Elustondo; Carla E Carvalho-Pinto; Dolores Rodríguez; Ruth Gómez-Caro; Joan De Jong; Carlos Martínez-A; Jan Paul Medema; Michael Hahne Journal: J Clin Invest Date: 2002-06 Impact factor: 14.808
Authors: N Roescher; J L Vosters; G Alsaleh; P Dreyfus; S Jacques; G Chiocchia; J Sibilia; P P Tak; J A Chiorini; X Mariette; Jacques-Eric Gottenberg Journal: Mol Ther Date: 2013-12-05 Impact factor: 11.454
Authors: Bruce J Baum; Ilias Alevizos; John A Chiorini; Ana P Cotrim; Changyu Zheng Journal: Expert Opin Biol Ther Date: 2015-07-06 Impact factor: 4.388
Authors: Arjun Sharma; Jeremy Kiripolsky; Ekaterina Klimatcheva; Alan Howell; Farzad Fereidouni; Richard Levenson; Thomas L Rothstein; Jill M Kramer Journal: Clin Immunol Date: 2016-01-28 Impact factor: 3.969